Symphony Allegro
2006
FOUNDED
M&A
STATUS
1-10
EMPLOYEES
M&A
LATEST DEAL TYPE
2
FINANCING ROUNDS
Description
Developer of Alexza Pharmaceuticals' AZ-002 and AZ-004 products. The company was formed through a collaboration between Symphony Capital Partners and Alexza Pharmaceuticals to develop Alexza's AZ-002 Staccato Alprazolam and AZ-004 Staccato Loxapine programs. It supports AZ-002 through Phase IIb clinical trials for the treatment of panic attack in patients with panic disorder and AZ-004 through Phase IIb clinical trials for the treatment of acute agitation in patients with schizophrenia.
Website
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Office
- 7361 Calhoun Place
- Suite 325
- Rockville, MD 20855
- United States
+1 (301) 000-0000
Symphony Allegro Valuation and Funding
| Deal Type | Date | Amount | Post-Val | Valuation/ EBITDA |
Debt | Status |
|---|
This information is reserved for PitchBook Platform users. To explore Symphony Allegro‘s full profile, request access.
Request full access to PitchBookSymphony Allegro Former Investors
| Investor Name | Investor Type | Holding | Participating Rounds | Investor Since | Board Seat | Contact Info |
|---|
This information is reserved for PitchBook Platform users. To explore Symphony Allegro‘s full profile, request access.
Request full access to PitchBook